Polku Therapeutics

Executive Summary

Polku Therapeutics is a Finnish biotechnology company founded in 2018, focused on developing first-in-class, disease-modifying small molecule therapies for neurodegenerative diseases. The company targets the root causes of neurodegeneration by modulating the PREP-PP2A axis, a master regulator of tau homeostasis, to clear toxic protein aggregates and reduce neuroinflammation. Its approach aims to restore the brain's natural protective mechanisms. Currently in the pre-clinical stage, Polku is advancing its lead candidates toward IND-enabling studies. The company's innovative science addresses a critical unmet need in diseases such as Alzheimer's and other tauopathies, where current treatments are largely symptomatic. With a strong scientific foundation and a novel mechanism of action, Polku represents an early-stage opportunity in the neurodegenerative space.

Upcoming Catalysts (preview)

• Q4 2026Announcement of preclinical proof-of-concept data for lead candidate60% success
• TBDPartnership or licensing deal for PREP-PP2A platform30% success
• Q2 2027IND application submission for lead program40% success